<SEC-DOCUMENT>0001144204-16-075366.txt : 20160113
<SEC-HEADER>0001144204-16-075366.hdr.sgml : 20160113
<ACCEPTANCE-DATETIME>20160113083029
ACCESSION NUMBER:		0001144204-16-075366
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160113
FILED AS OF DATE:		20160113
DATE AS OF CHANGE:		20160113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		161339961

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v428825_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">For the month of January, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">Commission File Number: <B>000-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B>XTL
Biopharmaceuticals Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>5 HaCharoshet St.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Raanana 4365603</B><BR>
<B>Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals
Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No.&nbsp;333-148085, File No. 333-148754
and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="xtllogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt; text-transform: uppercase"><B>XTL
Biopharmaceuticals advances formulation of its hcdr1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt; text-transform: uppercase"><B>drug for clincial trials in the treatment of lupus through</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt; text-transform: uppercase"><B>use of CYDEX Pharmaceuticals&rsquo;
captisol&reg; </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B><I>XTL
to formulate hCDR1 using Captisol&reg; in its advanced clinical studies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>RAANANA,
Israel</B></FONT><B> - (January 13, 2016) &ndash; XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) </B>(&ldquo;XTL&rdquo;
or the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus,
today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of
Captisol<FONT STYLE="text-transform: uppercase"><B>&reg;</B></FONT> in the formulation of its lead drug, hCDR1, for the treatment
of systemic lupus erythematosus (SLE).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement grants XTL a non-exclusive,
royalty-free license to use Captisol<FONT STYLE="text-transform: uppercase"><B>&reg; </B></FONT>in the formulation of its drug
for the purpose of conducting its advanced clinical study on hCDR1 for the treatment of SLE subject to the payment of certain milestone
and other payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Josh Levine, Chief Executive Officer of
XTL, commented, &ldquo;We are pleased with the completion of this strategic agreement with CyDex for the use and supply of Captisol<FONT STYLE="text-transform: uppercase"><B>&reg;</B></FONT>.
This partnership represents a key element of our preparations for the advanced clinical study of hCDR1 and together with our agreement
with BioConnection NV for the production of our drug product, we believe this will advance much of the chemistry manufacturing
and control activities required prior to IND approval.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;With our progress on the production
of the drug product and an FDA response to our proposed study design expected in early 2016, we are positioning ourselves to initiate
the trial in the second half of 2016. We believe that hCDR1 has the potential to be a &lsquo;first in class&rsquo; and &lsquo;best
in class&rsquo; drug in an area with a significant unmet medical need. There is currently no effective solution for SLE in the
market and the competitive pipeline is remarkably weak,&rdquo; Levine added.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About hCDR1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">hCDR1 is a novel compound with a unique
mechanism of action and with clinical data on over 400 patients in 3 clinical studies. The drug has a favorable safety profile,
is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint. For further information
please see a peer reviewed article in Lupus Science and Medicine journal (<FONT STYLE="color: Blue"><U>http://lupus.bmj.com/content/2/1/e000104.full</U></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: center">&nbsp;XTL Biopharmaceuticals Ltd.</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 Hacharoshet Street, Raanana, 43656, Israel</TD>
    <TD STYLE="text-align: center">Page 1</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Tel: +972 9 955 7080; email: <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Blue"><U>ir@xtlbio.com</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="xtllogo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Systemic Lupus Erythematosus (SLE)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lupus is a chronic autoimmune disease involving
many systems in the human body, including joints, kidneys, central nervous system, heart, hematological system and others. The
biologic basis of the disease is a defect in the immune (defense) system, leading to production of self (auto) antibodies, attacking
the normal organs and causing irreversible damage. According to the Lupus Foundation of America, at least 1.5 million Americans
have the disease (more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The majority of patients
are women of childbearing years. There has been only one drug approved by the FDA in the last over 50 years and recently two of
the few drugs in advanced development did not meet their primary endpoints in Phase 3 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Captisol&reg;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Captisol&reg; is a patent protected, uniquely modified cyclodextrin,
whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility,
stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About XTL Biopharmaceuticals Ltd.
(XTL)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd., a biopharmaceutical
company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical
needs with a focus on treatments for autoimmune diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is a public company, traded on the
Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices:
Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>www.xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">===============================================================</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: center">&nbsp;XTL Biopharmaceuticals Ltd.</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 Hacharoshet Street, Raanana, 43656, Israel</TD>
    <TD STYLE="text-align: center">Page 2</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Tel: +972 9 955 7080; email: <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Blue"><U>ir@xtlbio.com</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="xtllogo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Annual Report on Form 20-F as filed with
the U.S. Securities and Exchange Commission on April 28 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: center">&nbsp;XTL Biopharmaceuticals Ltd.</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 Hacharoshet Street, Raanana, 43656, Israel</TD>
    <TD STYLE="text-align: center">Page 3</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Tel: +972 9 955 7080; email: <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Blue"><U>ir@xtlbio.com</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><B>XTL BIOPHARMACEUTICALS LTD.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Date: January 13, 2016</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 23%; border-bottom: Black 1pt solid">/s/ Josh Levine</TD>
    <TD STYLE="vertical-align: top; width: 24%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Josh Levine</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Chief Executive Officer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtllogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtllogo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !A 3X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*\_P#C
M9\1-5^&/@NXUW2=%_MV2V.Z:V5B&$?<CU-?)7_#SY>0?!X4@X*F8Y!]#7K83
M*\7CH.IAXW2\T>;B<PPV$DH5I6;\F?>M%?#7A_\ X*::??:W96VI>&OL5E-(
MJ27"RD^6">M?:VA:[8^)=)MM2TVY2[LKA!)'+&<@@UEC,OQ6!M]8A:YIA<=A
M\9?V$KV+]%%%><=P445QGQ8^*FB_!_P?=Z_K<ZQPPK^[CS\TC=E JZ=.562A
M!7;(G.-.+E)V2.SHKX+;_@I_'O;9X1!3/RDS'.*3_AY^O_0H+_W^-?0?ZO9E
M_P ^OQ7^9XO]MX#_ )^?@S[UHKX*_P"'GZ_]"@O_ '^-'_#S]?\ H4%_[_&C
M_5W,O^?7XK_,/[;P'_/S\&?>M%?!7_#S]?\ H4%_[_&C_AY^O_0H+_W^-'^K
MN9?\^OQ7^8?VW@/^?GX,^]:*^"O^'GZ_]"@O_?XT?\//U_Z%!?\ O\:/]7<R
M_P"?7XK_ ##^V\!_S\_!GWK17P5_P\_7_H4%_P"_QH_X>?K_ -"@O_?XT?ZN
MYE_SZ_%?YA_;> _Y^?@S[UHKXC\&_P#!2!/%7BK3-'/A58/MDZP^9YQ.W)QF
MOMJ-Q(H8=QFO,QF Q&!:CB(V;V/0PN,H8Q.5"5TAU%%%>>=H4444 %%>4>._
MVAM#\!Z])I=W!-),B[BR#BNX\$^,+7QQH,&JVBLD,PR%;K7=5P.)HT8UZD&H
M2V?<X*6/PU>M+#TYISCNNQOT445PG>%%%% !1110 4444 %%%% !1110 444
M4 8_B+3S?6<B;0Z,I5E/((QTK\R/VM/V;IO ^L7'B70+5FTF=RUS"@_U+'O]
M*_4YE# @]*XKQSX+MO$&FW-O/ LT$R%'1AD$&O6RW,:N6UU5I[=5W1YN/P-/
M'T73GOT?9GXE\2+ZJ:^KOV,?VL)OA?J\'A/Q/=L_AFY<+!,_)MG/]*X#]I;]
MGV\^$OB";4+"!W\.W#Y5O^>+'L?:O$3\PX/T(K]AE'"YW@^\9?>G_FC\NC+$
M93BNTH_<U_DS]X[.[AOK6*XMY%F@E4.DB'(8'H14U?GU^P_^UL=-FMO 'BZ[
M)B=MFGWLS<+Z(2:^^-5UJRT72Y]2O;A(+*&,RO,QPH7&<YK\;S#+ZV7UW0J+
MT?='ZG@L;2QM%58/U\BAXR\8Z7X#\.WNM:O<QVME:QEV9VQG'8>IK\DOVE?V
MA]4^/OC&6X9I+;0+5BMG9[OE(_O'ZUU7[7O[3]W\;O$TNCZ5,T7A2QD*QJIQ
MY[ _>/K7SJ2%7VK])X?R58.*Q-=?O'LNR_S/@\ZS;ZU)X>B_<6_G_P  /3U/
M %6/[/O/^?.?_O@U].?LI_LSS^+;B+Q/K]KFP!_T:UD7[_\ M'VK[1A^!&BM
M&"=(M<_]<Z>8<34<'7=&G'GMN[]>P8'A^KBJ2JU)<M]E8_)+^S[S_GSG_P"^
M#1_9]Y_SYS_]\&OUQ_X4/HG_ $"+7_OW3)/@3HBH3_9%K_W[KS/]<(_\^?Q.
M_P#U7?\ S]_ _(R2&2%L2QO$WHXP:;7T#^VEX;M?"_Q(M[6TMX[:/R\[8Q@5
M\_#_ %B?[PK[C!8GZYAX8BUN97L?(8O#_5:\J%[V)EL;ME!6TF93T(0X-+_9
M]Y_SYS_]\&OTZ^#?P>T?6OAOX>NI-+MY'DM%8LR9)-=O_P *'T3_ *!%K_W[
MKXNIQ=&G.4/8[.VY]9#AESBI>UW\C\CO[/O/^?.?_O@U"RM&Q5U*,.JL,&OU
MPNO@9HD,3-_9%KP#_P L_:OS"^-%C'IOQ0URVB18XXY2 JC '->SE.>+-*LJ
M:I\ME?<\K,\G>74XU.?FN[;%7X3L5^)GAPC_ )_(_P#T(5^V&D2&2SC)Z[%_
MD*_$[X4_\E*\.?\ 7Y'_ .A"OVOT7_CSC_W%_D*^8XO_ (U'T?YGT/#'\&KZ
MK\C0HHHK\_/M J*X8K"Q%2U#=?\ 'N_TH&CX?^/TIF^(=VQZ^7BOHG]G&<MX
M#LD[ 5\Y?'C_ )*#>?[E?1'[-_\ R)%I]*_1\X_Y$6%^7Y'YGDO_ "/L5\_S
M1[%112!@>AS7YP?I8M%%% &%XP\::7X&TE]1U6?R8%X&.2Q]!6!X!^,WASXB
M74MKIL["ZC&XQR#!(]17*?M%>$KOQEX=AM[7/FVTOFJG]_VKSKX!_#?5M \6
M'4[^,VX5-BQ]S[U])A\+ET\MG7JU;5E>R_+3K<^8Q&+S*&9PH4J5Z+M=V^_7
MI8^K**9$Q:,$]:?7S9].%%%("&Y!S0 M%%% !1110 4UT$BE2.*=10!YE\4_
MAGI_C+0[NPO[9;FUF4AE8=/<>]?E;\=/@MJ7P<\426\R-)I4[DVUP <8_ND^
MM?LW-"LT95AFO&?C=\'=,^('AN\T_4(%>*1"5D8<QGU![5]#D^;3RRMKK3>Z
M_5>9XF:9;#,*6FDUL_T/R!5FC=9(W:.1"&1U."I'0BO8_&G[5GC?QQ\,=-\$
M7EV4L[9 D]TI(EN5'9CZ5YOXW\,#P9XKU'1ENX[Y;64H)HCD$>]8E?LDJ5#%
M*%645*VJ/RR-6MAN>E%VOHQJ@1K@< 5]!?LN?LZW7Q/UJ'6]5@*Z!;OE4<8\
M]AZ>U<3^S_\ "F+XN>/K;3+F[C@M8CYLD3-AI0.PK]7/ASX!LO#&DVUI:6ZV
M]M"H5(U&  *^3XBSEX2/U6A\;W?9?YL^ER/*EB7]9K?"MEW?^1I^#?"%MHNG
MP110K#%&H5(U& H':NM50HP!Q0JA% ' IU?DQ^DB;1Z5'<*/)?CM4M1W'^I?
MZ4 ?EW_P4%&/BY;_ /7*OE\?ZR/_ 'A7U!_P4&_Y*Y;_ /7*OE\?ZR/_ 'A7
M[GD?_(MH^A^/YM_O]7U/V8_9W4?\*D\*\?\ +DE>G[1Z5YC^SO\ \DD\*_\
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M]E:>\N',DLC')9CUK[SA[)/K#6+Q*]Q;+OY^GYGQN=YO[!/#4'[SW?;_ ()
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M]>8?L[_\DD\*_P#7DE>GU^)XC^-/U?YGZU1_A0]%^13U7_CSD_W3_*OQC_:
M_P"2Q>(_^NY_F:_9S5?^/.3_ '3_ "K\8_V@/^2Q>(_^NY_F:^UX1_WFI_A_
M4^4XF_W>'K^AD?"G_DI7AS_K\C_]"%?M?HO_ !YQ_P"XO\A7XH?"G_DI7AS_
M *_(_P#T(5^U^B_\><?^XO\ (5IQ?_&H^C_,CAC^#5]5^1H4445^?GV@5#=?
M\>[_ $J:H;K_ (]W^E SX<^.W'Q"NS_LU[!^SWX&CBT"&\= 7N?WFX]<>E>2
M?M 6LEK\0KC=_'&&%?1G[/.I0:EX%T_RF#20KY<OLU?HV;SG_86&4/A=K_=I
M^)^:9/"']O8IS^)7M]ZO^!ZA:V<5M&%50,"I6C5A@J,4^BOSD_2CD?&7A>#4
MK&13&"'!!KX=\6:;_P (_P")KRW3A8)MR>V#D5^@NJ;1:.7.% R37P/\2[R/
M4O&VK-#ROG,@([U]_P 'RG]9JQ^S;7[S\\XSC#ZM2E]KFT^X]H\=ZP^M? ^Q
MN97+R20@DGK7+_LSR^3K5ZWI$3^E:OB2![7X&V,4@PRPC(-8?[.G_(4OL?\
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H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
